December 13, 2024,LEXINGTON, Mass., Charlotte, N.C., United States : Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access BOT/BAL based on supporting clinical evidence and medical need.
Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines. The NPP ensures that patients, in consultation with their physicians, can access BOT/BAL even before regulatory approval, adhering to all ethical and compliance standards.
BOT and BAL are investigational immunotherapies designed to target challenging cancers, including MSS CRC and other tumors historically resistant to immune-based treatments. Clinical outcomes have demonstrated complete pathological responses in neoadjuvant MSS colon cancer patients and durable tumor responses across multiple cancer types. These results establish BOT/BAL as a treatment option with the potential to redefine standards of care for patients with difficult-to-treat cancers.
